Alteogen Announces Exclusive License Agreement with Tesaro, a Subsidiary of GSK, for the Development of a Subcutaneous Formulation of Dostarlimab Enabled by Hybrozyme™ Technology ...Middle East

DAEJEON, South Korea, Jan. 20, 2026 /PRNewswire/ -- Alteogen Inc. (KOSDAQ: 196170) announced today that the company has entered into an exclusive license agreement with Tesaro, Inc., a subsidiary of GSK. Under the terms of the agreement, Tesaro will acquire world-wide rights to use...

Hence then, the article about alteogen announces exclusive license agreement with tesaro a subsidiary of gsk for the development of a subcutaneous formulation of dostarlimab enabled by hybrozyme technology was published today ( Tuesday 20/01/2026 - 10:58 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Alteogen Announces Exclusive License Agreement with Tesaro, a Subsidiary of GSK, for the Development of a Subcutaneous Formulation of Dostarlimab Enabled by Hybrozyme™ Technology )

Also on site :

• Russia-Ukraine war: List of key events, day 1,426
• Rangers’ Cody Bradford Targeting Return In May From Elbow Surgery
• '90s Trash Metal Band Releases New Single Ahead of Farewell Album